drugset / Trial / NCT06813417
CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma
Phase 0
Active not recruiting
1 enrolled
University of Calgary
Alberta Health Services, Calgary · collabAlberta Precision Laboratories · collab
NaSingle-groupOpen-labelTreatment
Summary
A single patient study to determine whether GCAR1 is safe and effective for re-treatment of alveolar soft part sarcoma (ASPS) with GPNMB surface expression that has relapsed and is not responding to usual treatment.
Timeline
- Start
- 2025-01-30
- Primary completion
- 2030-01-30
- Completion
- 2030-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GCAR1 | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | GCAR1 | Cell therapy | 2.5e+07 cells/kg | Intravenous |